Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Allergan (AGN) a Great Stock for Value Investors?

by Zacks Equity Research

Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

Ironwood (IRWD) Q3 Earnings & Revenues Miss, Shares Down

by Zacks Equity Research

Ironwood Pharmaceuticals (IRWD) misses estimates for both earnings and sales in the third quarter. The company maintains its guidance for operating expenses.

Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO

by Zacks Equity Research

We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.

Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise

by Zacks Equity Research

Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.

Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

by Zacks Equity Research

Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

Is a Beat in Store for Editas (EDIT) This Earnings Season?

by Zacks Equity Research

On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.

Allergan (AGN) Beats on Q3 Earnings, Raises 2018 Guidance

by Zacks Equity Research

Allergan (AGN) beats third-quarter estimates for earnings and sales and raises its full-year guidance for both the metrics. Botox remains the primary sales driver.

Allergan (AGN) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Allergan (AGN) delivered earnings and revenue surprises of 5.99% and 1.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Teva (TEVA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals

5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings

by Zacks Equity Research

We take a look at a few stocks that might deliver an earnings beat when they report next week.

What's in the Cards for Glaxo (GSK) This Earnings Season?

by Zacks Equity Research

Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.

Why Earnings Season Could Be Great for Allergan (AGN)

by Zacks Equity Research

Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q3 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

Can Amgen (AMGN) Keep the Earnings Streak Alive in Q3?

by Zacks Equity Research

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

Universal Health Services (UHS) Q3 Earnings: A Beat in the Cards?

by Zacks Equity Research

United Health's (UHS) third quarter is likely to gain from solid segmental performances and higher number of admissions.

Is a Beat in the Cards for Allergan (AGN) in Q3 Earnings?

by Zacks Equity Research

While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Centene's (CNC) Earnings and Revenues Top Estimates in Q3

by Zacks Equity Research

Execution of growth strategy as well as the company's solid operating metrics leads Centene (CNC) to an earnings beat in Q3.

Allergan (AGN) Q3 Earnings Preview: What's in the Cards?

by Zacks Equity Research

Allergan (AGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

by Zacks Equity Research

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.

    What's in Store for Centene (CNC) This Earnings Season?

    by Zacks Equity Research

    Centene's (CNC) third quarter should exhibit strong performances by its Government-backed and Medicaid businesses.

      EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

      by Zacks Equity Research

      EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

        Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

        by Zacks Equity Research

        Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

        Neena Mishra headshot

        Invest Like Warren Buffett with These Stocks & ETF

        by Neena Mishra

        Moat investing, popularized by Buffett, looks for attractively priced companies with sustainable competitive advantages.

        Corium's (CORI) Shares Surge on Merger Agreement With Gurnet

        by Zacks Equity Research

        Corium International (CORI) announces merger agreement with Gurnet Point Capital. The deal values Corium at $12.50 per share in cash and will take the company private.